AspenBio Pharma, Inc.
AspenBio Pharma Appoints Dr. Mark Ratain to Board of Directors
emerging bio-pharmaceutical company dedicated to the development of novel
drugs and diagnostics for animals and humans, has appointed Dr. Mark J.
Ratain as a new independent member of its board of directors. His
appointment brings the total number of company directors to six, with four
Dr. Ratain is an accomplished and highly regarded hematologist/oncologist
and clinical pharmacologist. Since 1983, he has been affiliated with the
Department of Medicine at the University of Chicago, where he is currently
the Leon O. Jacobson Professor of Medicine and chairman of the Committee on
Clinical Pharmacology and Pharmacogenomics. He is also the associate
director for clinical sciences at the University of Chicago’s Cancer
Research Center. He serves on committees at Georgetown University and St.
Jude Children’s Research Hospital, and is a member of multiple professional
Dr. Ratain has authored and co-authored more than 300 articles and book
chapters, and participates in research review for the National Institutes
of Health. He is a past advisor to the Food and Drug Administration, and
was elected in 2007 to the American Association of Physicians.
He has been involved in the development of several anticancer agents, and
was the lead inventor on the FDA-approved UGT1A1 diagnostic to predict
irinotecan therapy, commercialized as a 510(k) device in 2005. He recently
received the Emil J. Freireich Award in Clinical Research from MD Anderson
Cancer Center in Houston.
Dr. Ratain is also a director of DATATRAK International, Inc., a technology
and services company focused on providing a platform of software
applications to the global clinical trials industry. He received his A.B.
Degree in Biochemical Sciences from Harvard University and his M.D. from
the Yale University School of Medicine.
“We are honored and fortunate to have Dr. Ratain join our board,” said Greg
Pusey, AspenBio Pharma’s chairman. “His award-winning expertise and
achievements in the world of medicine substantially enhances our board
leadership. Dr. Ratain joins us at an exciting period in the development of
AspenBio’s appendicitis test and single-chain animal products. We look
forward to benefiting from his extensive experience as we work to bring
these products to market.”
About AspenBio Pharma
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the
discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the nation’s
largest medical diagnostic companies and research institutions. The company
has successfully leveraged this foundational science and technology
expertise to rapidly develop an enviable late-stage pipeline of several
novel reproduction hormone analogs for wide-ranging therapeutic use
initially in bovine and equine species. AspenBio Pharma continues to
advance the development and testing of its two first-generation blood-based
human diagnostic tests designed to rapidly help diagnose or rule out
appendicitis in patients complaining of abdominal pain. For more
information, go to www.aspenbiopharma.com.
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89